William Blair Forecasts Higher Earnings for PTC Therapeutics

PTC Therapeutics, Inc. (NASDAQ:PTCT) – Stock analysts at William Blair boosted their FY2025 earnings estimates for PTC Therapeutics in a research report issued to clients and investors on Wednesday, November 5th. William Blair analyst S. Corwin now forecasts that the biopharmaceutical company will post earnings of $8.84 per share for the year, up from their previous estimate of $6.40. The consensus estimate for PTC Therapeutics’ current full-year earnings is ($4.52) per share. William Blair also issued estimates for PTC Therapeutics’ Q4 2025 earnings at ($0.57) EPS, Q1 2026 earnings at ($0.15) EPS, Q2 2026 earnings at ($0.28) EPS, Q3 2026 earnings at ($0.11) EPS, Q4 2026 earnings at $0.08 EPS and FY2026 earnings at ($0.45) EPS.

Other research analysts have also recently issued research reports about the company. Weiss Ratings restated a “hold (c-)” rating on shares of PTC Therapeutics in a research note on Wednesday, October 8th. Truist Financial lifted their price objective on PTC Therapeutics from $80.00 to $86.00 and gave the stock a “buy” rating in a report on Tuesday, July 29th. Bank of America lowered their target price on shares of PTC Therapeutics from $82.00 to $76.00 and set a “buy” rating on the stock in a research note on Wednesday, August 20th. Wall Street Zen raised shares of PTC Therapeutics from a “hold” rating to a “buy” rating in a report on Saturday. Finally, UBS Group lifted their price target on shares of PTC Therapeutics from $71.00 to $80.00 and gave the stock a “buy” rating in a research note on Tuesday, July 29th. Ten equities research analysts have rated the stock with a Buy rating, six have assigned a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and a consensus target price of $75.40.

PTC Therapeutics Trading Down 1.1%

PTCT stock opened at $71.78 on Friday. The stock’s 50 day simple moving average is $63.31 and its 200 day simple moving average is $53.60. PTC Therapeutics has a 12-month low of $35.95 and a 12-month high of $73.98. The stock has a market capitalization of $5.70 billion, a PE ratio of 10.30 and a beta of 0.60.

PTC Therapeutics (NASDAQ:PTCT) last posted its quarterly earnings results on Tuesday, November 4th. The biopharmaceutical company reported $0.20 EPS for the quarter, beating analysts’ consensus estimates of ($1.19) by $1.39. The firm had revenue of $211.01 million for the quarter, compared to analysts’ expectations of $177.42 million. PTC Therapeutics had a net margin of 35.65% and a negative return on equity of 106.31%. The business’s revenue for the quarter was up 7.2% on a year-over-year basis. During the same quarter in the prior year, the company posted ($1.39) earnings per share. PTC Therapeutics has set its FY 2025 guidance at EPS.

Hedge Funds Weigh In On PTC Therapeutics

A number of institutional investors have recently bought and sold shares of the stock. AlphaQuest LLC raised its stake in shares of PTC Therapeutics by 337.7% in the second quarter. AlphaQuest LLC now owns 7,909 shares of the biopharmaceutical company’s stock worth $386,000 after buying an additional 6,102 shares during the period. Allspring Global Investments Holdings LLC purchased a new stake in PTC Therapeutics in the 1st quarter worth approximately $524,000. Sector Gamma AS increased its holdings in PTC Therapeutics by 41.4% in the 1st quarter. Sector Gamma AS now owns 92,250 shares of the biopharmaceutical company’s stock worth $4,701,000 after acquiring an additional 27,000 shares in the last quarter. Deutsche Bank AG raised its stake in PTC Therapeutics by 262.1% during the 1st quarter. Deutsche Bank AG now owns 341,724 shares of the biopharmaceutical company’s stock worth $17,414,000 after acquiring an additional 247,346 shares during the period. Finally, Cerity Partners LLC bought a new stake in PTC Therapeutics during the 1st quarter worth approximately $641,000.

Insider Transactions at PTC Therapeutics

In other PTC Therapeutics news, insider Neil Gregory Almstead sold 55,000 shares of the stock in a transaction that occurred on Friday, October 3rd. The shares were sold at an average price of $66.05, for a total value of $3,632,750.00. Following the transaction, the insider directly owned 100,625 shares in the company, valued at approximately $6,646,281.25. This trade represents a 35.34% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, Director Emma Reeve sold 25,562 shares of PTC Therapeutics stock in a transaction on Friday, October 3rd. The stock was sold at an average price of $65.96, for a total transaction of $1,686,069.52. Following the transaction, the director owned 10,332 shares in the company, valued at $681,498.72. This represents a 71.22% decrease in their position. The SEC filing for this sale provides additional information. Over the last ninety days, insiders have sold 254,662 shares of company stock worth $16,000,821. 5.50% of the stock is currently owned by corporate insiders.

PTC Therapeutics Company Profile

PTC Therapeutics, Inc, a biopharmaceutical company, focuses on the discovery, development, and commercialization of medicines to patients with rare disorders in the United States and internationally. The company offers Translarna and Emflaza for the treatment of Duchenne muscular dystrophy; Upstaza to treat aromatic l-amino acid decarboxylas (AADC) deficiency, a central nervous system disorder; Tegsedi and Waylivra for the treatment of rare diseases; and Evrysdi to treat spinal muscular atrophy (SMA) in adults and children.